🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

II edición del PRECEPTORSHIP EN NASH (8,9,10 octubre) del Hospital Marqués de Valdecilla, organizado por Javier Crespo, Mayte Arias-Loste y Paula Iruzubieta. Una oportunidad para debatir sobre una enfermedad que nos ocupará las próximas décadas. Asociación Española para el Estudio del Hígado Sociedad Española de Patología Digestiva (SEPD)

The future of testing in NASH using metabolics ;) great science and promising easy scores to identify at risk NASH. @OWLMetabolomics Cristina Alonso EASLnews

Introducing MASEF:🩸metabolomics based to assess at-risk NASH (NASH w NAS ≥4 + ≥F2) 👉🏻Performed Similar to FAST 👉🏻 FIB-4+MASEF = FIB-4 + VCTE 👉🏻International Multicenter 📖 #livertwitter Quentin M. Anstee Naim Alkhouri Phil Newsome @OWLMetabolomics Elliot Tapper pubmed.ncbi.nlm.nih.gov/37505221/

🩺 #NASH & #NALFD can be challenging to manage, but a new study offers promising insight into determining progression & regression rates – read more on ow.ly/58Kh50Pa9og #LiverHealth #MedicalResearch #HealthInsights #PanNASH #ResearchUpdate

An extraordinary coordination work that culminates in a series of recommendations that, YES or YES, we should implement in the coming years. ¡¡Healthy Livers, Healthy Lives¡¡ Jeffrey V. Lazarus EASLnews AASLD Asociación Española para el Estudio del Hígado Sociedad Española de Patología Digestiva (SEPD) #livertwitter journals.lww.com/hep/Abstract/9…

A blood test to diagnose NASH and significant fibrosis (NASH >=F2). Will be available in the US within few months #livertwitter #gitwitter Novo Nordisk US Medical Madrigal Pharmaceuticals akerotx The Innovation | Medicine VCU Stravitz-Sanyal Institute for Liver Disease Naim Alkhouri Juan Pablo (JP) Arab, MD  Rebeca Mayo @OWLMetabolomics Cristina Alonso

#HEP_highlights: This new score for at-risk MASH is absolutely MASEF! The serum-based Metabolomics-Advanced Steatohepatitis Fibrosis (MASEF) score can accurately identify MASH with ≥F2 fibrosis #LiverTwitter Mazen Noureddin, MD, MHSc shorturl.at/coTV1

#Resmetirom is the first FDA drug to be approved for NASH/MASH patients without cirrhosis! #livertwitter it took long years but what a rewarding journey for those who were part of it! Happy for our patients. More work to be done Madrigal Pharmaceuticals AASLD Houston Methodist MD

It is with a heavy heart that we at the Fatty Liver Alliance share the news of the sudden passing of Dr. Stephen A. Harrison, a distinguished hepatologist and cherished colleague to so many, on April 23, 2024. Dr. Harrison was a towering figure in the medical community, renowned

🗣️Jesús Bañales: "en torno al 40% de las mutaciones en #colangiocarcinoma son regulables". 📢 El doctor Jesus Bañales (San Sebastián) expone varios resultados de tratamientos en mutaciones de este tipo de carcinoma en su ponencia en las Jornadas. 👍 #liverTwitter #hepatologia

📅 @OWLMetabolomics attends EASLnews Congress 2024! Meet our team at Tech Village Booth BT4 🔬 Learn about our expertise in #LiverHealth and #ClinicalPractice. 💼We are waiting for you. #EASL2024

En #WeShareEASL nos interesa todo, incluída la ciencia básica. Especialmente si nos la explica el rock star Jesus Bañales: ⭐️ Nuevas dianas en hepatoblastoma ⭐️ Colangiocarcinoma ⭐️ #CEP y riesgo de CCA ⭐️ Poliquistosis hepática ⭐️ Passion Incluye varios guiños: 08:35

📊 Boost your data modeling skills with our "Data Modeling and Validation" ebook chapter! 🔵 Accurate models 🟠 Rigorous validation 🔵 Data integrity 🟠 Advanced tools 🚀 Access your FREE chapter now at bit.ly/4bQ9HsE! #DataScience #DataModeling #MachineLearning

📢 Excited to announce our participation at #INASL2024! Join us from August 7-10 to learn about our one-step diagnosis with the OWLiver test. Also, we will be presenting a poster about OWLiver. We're looking forward to starting validation with the Indian population soon. 🇮🇳

INASL-2024 7th to 10th August, 2024 Kochi, Kerala

A paper with a lot of impact on patients at higher risk of #MASLD progression: 1⃣The OWLiver Panel correctly classified 86%, 78.8% and 90.7% as MASH, at‐risk MASH and advanced fibrosis, respectively. EASLnews UEGJ my_UEG Asociación Española para el Estudio del Hígado Sociedad Española de Patología Digestiva (SEPD) onlinelibrary.wiley.com/doi/epdf/10.10…

2⃣A one‐step screening strategy using the OWLiver Panel can accurately predict the presence of MASH and at‐risk MASH in subjects at high risk of MASH progression. Paula Iruzubieta Rebeca Mayte Arias Loste Javier Ampuero Agustín Albillos Jose Luis Calleja Manuel Romero-Gómez RAF Asociación Española para el Estudio del Hígado

Rubió Metabolomics contributed to a study in the United European Gastroenterology Journal on #NonInvasiveDiagnosis of #MASH & fibrosis using OWLiver in collaboration with Dr. Paula Iruzubieta, Javier Crespo. 🔗Read the full study here: bit.ly/46Eiop8?utm_ca… #Hepatology #NITs

One more year happy to be here in INASL!

Today we are presenting the abstract: "One-step diagnosis of MASH and fibrosis in high risk population" using OWLiver Panel at the 2024 INSAL meeting in Kochi, that was also selected for oral presentation. Thanks to all the authors who participated in the study!!